Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has been assigned a consensus recommendation of “Reduce” from the twelve brokerages that are currently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $8.20.
Several research firms have issued reports on FULC. Truist Financial lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a research report on Tuesday, June 2nd. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price objective on the stock. in a research report on Tuesday, June 2nd. Cantor Fitzgerald cut shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Leerink Partners cut shares of Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 price objective on the stock. in a research report on Tuesday, June 2nd. Finally, Jefferies Financial Group set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Tuesday, June 2nd.
Check Out Our Latest Report on Fulcrum Therapeutics
Hedge Funds Weigh In On Fulcrum Therapeutics
Fulcrum Therapeutics Price Performance
Shares of NASDAQ:FULC opened at $3.50 on Thursday. Fulcrum Therapeutics has a 12 month low of $2.83 and a 12 month high of $15.74. The stock has a market cap of $233.21 million, a price-to-earnings ratio of -3.04 and a beta of 2.93. The stock’s 50 day moving average price is $6.32 and its 200 day moving average price is $8.63.
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last announced its earnings results on Monday, April 27th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.06. On average, sell-side analysts expect that Fulcrum Therapeutics will post -0.76 EPS for the current year.
Fulcrum Therapeutics Company Profile
Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.
Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.
Featured Stories
- Five stocks we like better than Fulcrum Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
